Europe may delay transparency

Share this article:

The push for clinical trial transparency may be delayed. Pharmalot reports that the European Medicines Agency is wading through more than 1,000 comments supporting the initiative and vociferous attacks from the industry and its backers who claim the initiative will threaten patient safety and corporate intellectual property. Threats to pack up and take jobs elsewhere have also accompanied industry concerns.

The EMA planned on having data out in the open by January 2104. It will decide in December if this date is still possible.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.